Please Wait...

TIMP-1 // Tissue Inhibitor of Metalloproteinase 1

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

The MMPs family comprises at least 24 different MMPs with high sequence similarity in their catalytic domains. MMPs are synthetized as pro-enzymes which are inactive until removal of their pro-domain (Löffek et al., 2011; Nagase and Woessner, 1999). Tissue Inhibitor of Metalloproteinase family comprises 4 members. They are two-domain proteins with a N-Terminal domain of approximately 125 residues and a C terminal domain of about 65 residues (Brew et al., 2000). TIMPs complexes with MMPs and interact with the catalytic domain of MMPs, that results in inhibition of the MMP activity (Gomis-R et al., 1997). Mature TIMP-1 protein is a 28kDa protein which inhibit all MMPs (but is a poor inhibitor of Membrane Type (MT1-MMP, MT3-MMP, MT5-MMP and MMP19). It also bind proMMP-9 and inhibit ADAM10 (Murphy, 2011).

Bioclinica Lab employs a manual sandwich immunoassay for TIMP-1 measurement in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (4 weeks ago)